Oppenheimer Maintains Outperform on ResMed, Raises Price Target to $205

ResMed Inc. -1.80%

ResMed Inc.

RMD

209.43

-1.80%

Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE: RMD) with a Outperform and raises the price target from $185 to $205.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via